Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis

Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain

(2013) Antonio García-Merino   Expert Review of Neurotherapeutics

Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines

(2013) Ralf Gold et al.   Expert Review of Neurotherapeutics

A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers

(2013) Colin Stott et al.   SpringerPlus

A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray

(2012) C. G. Stott et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray

(2012) C. G. Stott et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis

(2012) Michael G. Serpell et al.   JOURNAL OF NEUROLOGY

Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis

(2012) Lanting Lu et al.   PHARMACOECONOMICS

Sativex® in multiple sclerosis spasticity: a cost–effectiveness model

(2012) John Slof et al.   Expert Review of Pharmacoeconomics & Outcomes Research

The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis

(2012) David Baker et al.   Multiple Sclerosis and Related Disorders

Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration

(2011) E L Karschner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Role of Cannabinoids in Multiple Sclerosis

(2011) John P. Zajicek et al.   CNS DRUGS

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)

(2011) W Notcutt et al.   Multiple Sclerosis Journal

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis

(2010) Derick T Wade et al.   Multiple Sclerosis Journal

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

(2010) C. Collin et al.   NEUROLOGICAL RESEARCH

Validity, reliability, and clinical importance of change in a 0—10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

(2008) John T. Farrar et al.   CLINICAL THERAPEUTICS

Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors

(2007) G Pryce et al.   BRITISH JOURNAL OF PHARMACOLOGY